Mike Montemarano, Associate Editor 04.09.21
According to new evidence taken from the NiPPeR study (Nutritional Intervention Preconception and during Pregnancy to maintain healthy glucose levels and offspring health), a specific blend of myo-inositol, probiotics, and micronutrients developed by the international EpiGen Global Research Consortium and Nestlé Research was able to significantly decrease incidence of preterm birth when consumed before and during pregnancy.
During the trial, researchers assessed the effects of the nutritional supplement on maintaining healthy blood sugar levels and sustaining a healthy pregnancy and delivery. The supplement was found to decrease the incidence of preterm birth, particularly preterm birth associated with the premature rupture of membranes before the onset of labor. However, while the supplement was designed initially to balance blood sugar levels in pregnant women, no effects on gestational glycemia were observed.
“Maternal and infant nutrition are equally important in the first 1,000 days of life,” Dr. Isabelle Bureau-Franz, head of Nestlé research, said. “We are focused on discovering science-based solutions for mothers and their infants during preconception, pregnancy, and while breastfeeding. The NiPPeR study is a great example of how a public-private partnership can jointly build scientific evidence on the nutritional interventions in a largely understudied group.”
The NiPPeR trial is one of the largest randomized controlled trials studying preconception nutritional interventions on an international level. Over 1,700 women from the U.K., New Zealand, and Singapore who were planning pregnancy participated in the study. During the study, 585 participants conceived within one year, completing the primary outcome – 295 people were in the intervention group, while 290 participants were controls. The authors observed a 5.8% preterm birth rate in the intervention group, significantly lower than the control group, which saw a 9.2% preterm birth rate.
Findings from the study were recently published in Diabetes Care, a peer-reviewed medical journal.
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at mmontemarano@rodmanmedia.com.
During the trial, researchers assessed the effects of the nutritional supplement on maintaining healthy blood sugar levels and sustaining a healthy pregnancy and delivery. The supplement was found to decrease the incidence of preterm birth, particularly preterm birth associated with the premature rupture of membranes before the onset of labor. However, while the supplement was designed initially to balance blood sugar levels in pregnant women, no effects on gestational glycemia were observed.
“Maternal and infant nutrition are equally important in the first 1,000 days of life,” Dr. Isabelle Bureau-Franz, head of Nestlé research, said. “We are focused on discovering science-based solutions for mothers and their infants during preconception, pregnancy, and while breastfeeding. The NiPPeR study is a great example of how a public-private partnership can jointly build scientific evidence on the nutritional interventions in a largely understudied group.”
The NiPPeR trial is one of the largest randomized controlled trials studying preconception nutritional interventions on an international level. Over 1,700 women from the U.K., New Zealand, and Singapore who were planning pregnancy participated in the study. During the study, 585 participants conceived within one year, completing the primary outcome – 295 people were in the intervention group, while 290 participants were controls. The authors observed a 5.8% preterm birth rate in the intervention group, significantly lower than the control group, which saw a 9.2% preterm birth rate.
Findings from the study were recently published in Diabetes Care, a peer-reviewed medical journal.
Mike Montemarano has been the Associate Editor of Nutraceuticals World since February 2020. He can be reached at mmontemarano@rodmanmedia.com.
